Michael Rada’s Post

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.   Recently, AstraZeneca unveiled its new Bold Ambition during the Global Investor’s Day setting the stage for 2030! Aspiring to be pioneers in science, focused on transform patient outcomes, by 2030, globally we will deliver 20 new medicines, industry leading growth and aim to be carbon negative.   In India, we have recently announced our financial results for FY 2023-24 with 29% growth in revenue, which is one of our strongest years of performance. We owe this our talented, committed and passionate group of employees who go above and beyond in terms of achieving greater milestones every single day to transform the lives of patients. Proud to be part of a company that is unlocking the power of what science can do for people, society and the planet.   Read more here: https://lnkd.in/gtJHuUeK   #ScienceCan #AZProud

clearly a successful merger back in 1999 -

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation 

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation

🔍 What’s stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! 🌍 Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! 🌟 Here’s our simple 3-step proposal: 1️⃣ Meet with eMQT to discuss your therapeutic area and patient population focus. 2️⃣ We identify suitable sites and countries in Africa to match your needs. 3️⃣ Collaborate with us to build Centres of Excellence! Let’s lead the way in transforming clinical research.💡🤝 #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! 🌟 https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess

Today marks a significant milestone in our strategic journey, our commitment to achieving industry-leading growth by reaching $80 billion in total revenue by 2030. This ambition is a testament to our commitment to pushing the boundaries of science for people, society, and the planet. Excited about AstraZeneca's bold ambition to deliver $80bn in annual revenue by 2030! 🚀 We’ll see significant growth in our oncology, biopharmaceuticals and rare disease portfolios, launch 20 new medicines before the end of the decade and leverage transformative technologies to drive innovation. As we continue to grow in all therapy areas, we will continue to decouple carbon emissions from our increase in revenue, halving emissions across our value chain by 2030. 🌱 Let’s work together to unlock the power of what science can do for people, society and the planet. #AZN #WhatScienceCanDo

What’s meaningful to my work here at AstraZeneca? Beyond our dedication to advancing healthcare in Vietnam and ensuring equitable access to the latest and most effective treatments over our 30-year presence in the country, it is the meaningful collaboration and mutual trust we nurture with our stakeholders and partners that truly stand out. On September 30, 2024, I had the privilege of meeting with Vice Minister of the Ministry of Health, Mr. Do Xuan Tuyen, to discuss our ongoing and future contributions to Vietnam’s healthcare landscape. During this meeting, we outlined AstraZeneca Vietnam's key activities in: 💡Pharmaceutical Research and Development 💡Technology Transfer Projects aimed at producing advanced drugs locally. 💡Community Investment Programs aimed at creating an equitable and sustainable healthcare system, enhancing Vietnamese patients' access to advanced medications and treatments. We reaffirmed our alignment with Vietnam’s National Strategy for Pharmaceutical Industry Development and the National Program for Domestic Pharmaceutical Production by 2030, with a vision extending to 2045. Our goal is to support Vietnam in becoming a central hub for producing original brand-name drugs in the ASEAN region. Vice Minister Do Xuan Tuyen expressed high appreciation for AstraZeneca’s contributions and support over the years, particularly during the Covid-19 pandemic. He acknowledged our efforts in technology transfer, clinical trials, disease prevention and control, and our commitment to building a sustainable healthcare system. I felt both supported and encouraged after our discussion. With continued collaboration and support from the Ministry of Health, I am confident that we can achieve remarkable outcomes that benefit our people, society, and the planet. Picture below was taken with Vice Minister Do Xuan Tuyen in Hanoi. More information in Vietnamese: https://lnkd.in/gUH-auz3

Today in the spotlight ✨ Janssen: Collaboration for a healthy future ✨ Michel van Agthoven | Head Janssen/Johnson & Johnson Campus The Netherlands: “𝘛𝘩𝘦 𝘋𝘶𝘵𝘤𝘩 𝘓𝘪𝘧𝘦 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 & 𝘏𝘦𝘢𝘭𝘵𝘩 𝘦𝘤𝘰𝘴𝘺𝘴𝘵𝘦𝘮 𝘪𝘴 𝘢𝘵𝘵𝘳𝘢𝘤𝘵𝘪𝘷𝘦, 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘳𝘦𝘴𝘦𝘯𝘤𝘦 𝘰𝘧 𝘩𝘪𝘨𝘩𝘭𝘺 𝘦𝘥𝘶𝘤𝘢𝘵𝘦𝘥 𝘵𝘢𝘭𝘦𝘯𝘵, 𝘵𝘰𝘱 𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘢𝘯𝘥 𝘢 𝘷𝘪𝘣𝘳𝘢𝘯𝘵 𝘣𝘪𝘰𝘵𝘦𝘤𝘩 𝘴𝘵𝘢𝘳𝘵-𝘶𝘱 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 - 𝘢𝘭𝘭 𝘤𝘭𝘰𝘴𝘦 𝘵𝘰 𝘦𝘢𝘤𝘩𝘰𝘵𝘩𝘦𝘳. 𝘛𝘩𝘪𝘴 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘢𝘮𝘱𝘭𝘦 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘧𝘰𝘳 𝘤𝘳𝘰𝘴𝘴-𝘧𝘦𝘳𝘵𝘪𝘭𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯. 𝘞𝘦 𝘢𝘳𝘦 𝘤𝘰𝘮𝘮𝘪𝘵𝘵𝘦𝘥 𝘵𝘰 𝘧𝘶𝘦𝘭 𝘵𝘩𝘪𝘴 𝘦𝘤𝘰𝘴𝘺𝘴𝘵𝘦𝘮 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘰𝘶𝘳 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱𝘴 𝘸𝘪𝘵𝘩 𝘩𝘰𝘴𝘱𝘪𝘵𝘢𝘭𝘴, 𝘶𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘪𝘦𝘴, 𝘢𝘯𝘥 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘛𝘕𝘖, 𝘙𝘢𝘥𝘣𝘰𝘶𝘥 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘢𝘯𝘥 𝘙𝘢𝘥𝘣𝘰𝘶𝘥 𝘜𝘔𝘊, 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 𝘰𝘧 𝘓𝘦𝘪𝘥𝘦𝘯 𝘢𝘯𝘥 𝘓𝘜𝘔𝘊. 𝘞𝘦 𝘧𝘪𝘳𝘮𝘭𝘺 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘩𝘢𝘵 𝘣𝘺 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯, 𝘸𝘦’𝘳𝘦 𝘤𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘢 𝘧𝘶𝘵𝘶𝘳𝘦 𝘸𝘩𝘦𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘪𝘴 𝘢 𝘵𝘩𝘪𝘯𝘨 𝘰𝘧 𝘵𝘩𝘦 𝘱𝘢𝘴𝘵.” Janssen is one of the showcase companies in our bidbook 'Welcome to the Netherlands: Europe's Connected Life Sciences & Health Metropolis'. Together, as pharmaceutical company of Johnson & Johnson, Janssen regards end-to-end activities for medicines and vaccines from lab to patient. This covers research & development at Janssen Vaccines & Prevention, manufacturing at Janssen Biologics, and distribution and marketing at Janssen the Netherlands. Want to read more about Janssen and other companies located in The Netherlands? Have a look in our bidbook and find out why the Netherlands is an attractive place for innovative business: https://lnkd.in/eQYeTd8J TNO Radboud University Radboudumc Universiteit Leiden Leiden University Medical Center The Janssen Pharmaceutical Companies of Johnson & Johnson Janssen Europe, Middle East & Africa (EMEA)

This looks a great Cambridge 🇬🇧 event in April to consider how to make better Target Selection choices in #drugdiscovery and #commercial R&D for #patients. Hope to see you there 🤓💬🧬🔬🧫 #whatsciencecando #investmentdecisions #translationalresearch #translationalmedicine

Are you attending the World Orphan Drug Congress April 23 - 25th in Boston? If you haven't made a decision yet, here are 3 reasons to attend: 1. #1 Networking opportunity in the rare disease and orphan drug space: The event brings together key stakeholders from across the orphan drug ecosystem, including pharmaceutical companies, biotechs, patient advocacy groups, regulatory agencies, and investors. Networking at the event provides attendees with the chance to forge valuable connections, collaborate on projects, and explore potential partnerships that can drive innovation and advance research in orphan drug development. 2. Access to Industry Insights and Expertise: The event features 3-days of insightful and inspiring presentations, keynote sessions, workshops, roundtables, and so much more led by leading experts and thought leaders in the field of rare diseases and orphan drugs. 3. Learning and Education: whether you’re a researcher clinician, industry executive, or policymaker, WODC will enhance your knowledge base, deepen your understanding of rare diseases, and keep you up to date on the latest advances in orphan drug development and patient care. And if you need another reason, I'll be there and I'd love to connect with you! If you are planning to attend, leave me a comment and let's connect!! #raredisease #rarediseases #rareaccessactionproject #WODC #smallbiopharma